4 results  1 of 1 

1 Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience
Gaurav Prakash, Arihant Jain, Kamalkant Sahu, Amanjit Bal, Charanpreet Singh, Rajender Basher, Harmandeep Singh, Kundan Mishra, Aditya Jandial, Deepesh Lad, Alka Khadwal, Radhika Srinivasan, Ashim Das, Neelam Varma, Subhash Varma, Pankaj Malhotra
Blood Res.2021;56(3):134-140.   Published online 2021 September 30     DOI: http://dx.doi.org/10.5045/br.2021.2021039
      
2 Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma
Munira Shabbir-Moosajee, Samad Jehangir, Sobiya Sawani, Tariq Muhammed, Natasha Ali, Usman Sheikh, Salman Adil
Blood Res.2019;54(2):108-113.   Published online 2019 June 25     DOI: http://dx.doi.org/10.5045/br.2019.54.2.108
      
3 Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
Adam M. Greenbaum, Damian J. Green, Leona A. Holmberg, Ted Gooley, Brian G. Till, Lihua E. Budde, Heather Rasmussen, Oliver W. Press, Ajay K. Gopal
Blood Res.2018;53(3):223-226.   Published online 2018 September 28     DOI: http://dx.doi.org/10.5045/br.2018.53.3.223
      
4 Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
Seok Jin Kim, Soo-Mee Bang, Yoon Seok Choi, Deog-Yeon Jo, Jin Seok Kim, Hyewon Lee, Hyeon Seok Eom, Dok Hyun Yoon, Cheolwon Suh, Je-Jung Lee, Junshik Hong, Jae Hoon Lee, Youngil Koh, Kihyun Kim, Sung-Soo Yoon, Chang-Ki Min,
Blood Res.2016;51(3):193-199.   Published online 2016 September 23     DOI: http://dx.doi.org/10.5045/br.2016.51.3.193
      

 1 of 1